Internalized HIV Stigma, ART Initiation and HIV-1 RNA Suppression in South Africa: Exploring Avoidant Coping as a Longitudinal Mediator by Earnshaw, Valerie A. et al.
Portland State University 
PDXScholar 
OHSU-PSU School of Public Health Faculty 
Publications and Presentations OHSU-PSU School of Public Health 
10-2018 
Internalized HIV Stigma, ART Initiation and HIV-1 
RNA Suppression in South Africa: Exploring Avoidant 
Coping as a Longitudinal Mediator 
Valerie A. Earnshaw 
University of Delaware 
Laura M. Bogart 
RAND Corporation 
Jean-Philippe Laurenceau 
University of Delaware 
Brian T. Chan 
Harvard Medical School 
Brendan G. Maughan-Brown 
University of Cape Town 
See next page for additional authors 
Follow this and additional works at: https://pdxscholar.library.pdx.edu/sph_facpub 
 Part of th Community Healt  Commons, Immune System Diseases Commons, and the Virus 
Diseases Commons 
Let us know how access to this document benefits you. 
Citation Details 
Earnshaw, V. A., Bogart, L. M., Laurenceau, J.-P., Chan, B. T., Maughan-Brown, B. G., Dietrich, J. J., … Katz, I. 
T. (2018). Internalized HIV stigma, ART initiation and HIV-1 RNA suppression in South Africa: exploring 
avoidant coping as a longitudinal mediator. Journal Of The International AIDS Society, 21(10), e25198. 
This Article is brought to you for free and open access. It has been accepted for inclusion in OHSU-PSU School of 
Public Health Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact 
us if we can make this document more accessible: pdxscholar@pdx.edu. 
Authors 
Valerie A. Earnshaw, Laura M. Bogart, Jean-Philippe Laurenceau, Brian T. Chan, Brendan G. Maughan-
Brown, Janan Dietrich, Ingrid Courtney, Gugu Tshabalala, Catherine Orrell, Glenda E. Gray, David 
Bangsberg, and Ingrid T. Katz 
This article is available at PDXScholar: https://pdxscholar.library.pdx.edu/sph_facpub/172 
RESEARCH ARTICLE
Internalized HIV stigma, ART initiation and HIV-1 RNA
suppression in South Africa: exploring avoidant coping as a
longitudinal mediator
Valerie A Earnshaw1§ , Laura M Bogart2, Jean-Philippe Laurenceau3, Brian T Chan4,5 ,
Brendan G Maughan-Brown6 , Janan J Dietrich7, Ingrid Courtney8, Gugulethu Tshabalala7, Catherine Orrell8,
Glenda E Gray7,9, David R Bangsberg10 and Ingrid T Katz4,5,11,12
Corresponding author: Valerie A Earnshaw, 111 Alison Hall West, Newark, Delaware 19716, USA. Tel: 302 831 4772. (earnshaw@udel.edu)
Abstract
Introduction: Cross-sectional evidence suggests that internalized HIV stigma is associated with lower likelihoods of antiretro-
viral therapy (ART) initiation and HIV-1 RNA suppression among people living with HIV (PLWH). This study examined these
associations with longitudinal data spanning the first nine months following HIV diagnosis and explored whether avoidant cop-
ing mediates these associations.
Methods: Longitudinal data were collected from 398 South African PLWH recruited from testing centres in 2014 to 2015.
Self-report data, including internalized stigma and avoidant coping (denying and distracting oneself from stressors), were col-
lected one week and three months following HIV diagnosis. ART initiation at six months and HIV-1 RNA at nine months were
extracted from the South Africa National Health Laboratory Service database. Two path analyses were estimated, one testing
associations between internalized stigma, avoidant coping and ART initiation, and the other testing associations between inter-
nalized stigma, avoidant coping and HIV-1 RNA suppression.
Results: Participants were 36 years old, on average, and 63% identified as female, 18% as Zulu and 65% as Xhosa. The two
path models fit the data well (ART initiation outcome: X2(7) = 8.14, p = 0.32; root mean square error of approximation
(RMSEA) = 0.02; comparative fit index (CFI) = 0.92; HIV-1 RNA suppression outcome: X2(7) = 6.58, p = 0.47; RMSEA = 0.00;
CFI = 1.00). In both models, internalized stigma one week after diagnosis was associated with avoidant coping at three
months, controlling for avoidant coping at one week. In turn, avoidant coping at three months was associated with lower likeli-
hood of ART initiation at six months in the first model and lower likelihood of HIV-1 RNA suppression at nine months in the
second model. Significant indirect effects were observed between internalized stigma with ART non-initiation and unsup-
pressed HIV-1 RNA via the mediator of avoidant coping.
Conclusions: Internalized stigma experienced soon after HIV diagnosis predicted lower likelihood of ART initiation and HIV-1
RNA suppression over the first year following HIV diagnosis. Avoidant coping played a role in these associations, suggesting
that PLWH who internalize stigma engage in greater avoidant coping, which in turn worsens medication- and health-related
outcomes. Interventions are needed to address internalized stigma and avoidant coping soon after HIV diagnosis to enhance
treatment efforts during the first year after HIV diagnosis.
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1 | INTRODUCTION
The Joint United Nations Programme on HIV/AIDS’ (UNAIDS)
goals for addressing the HIV epidemic include that 95% of
people who have been diagnosed with HIV will have initiated
antiretroviral therapy (ART) and 95% of people receiving ART
will have suppressed HIV-1 RNA by 2030 [1]. Initiating ART is
a key step in the treatment cascade and necessary to achieve
HIV-1 RNA suppression, which in turn extends the lives of
people living with HIV (PLWH) and prevents the transmission
of HIV to others [2-5]. Reaching the goals set by UNAIDS
may be difficult in places like South Africa, where only 61% of
7.2 million PLWH were receiving ART and 47% had sup-
pressed HIV-1 RNA in 2017 [6]. HIV stigma has long been
recognized as a barrier to treatment and physical health
among PLWH in South Africa and globally [7-9]; yet, the medi-
ating mechanisms linking HIV stigma with treatment and phys-
ical health outcomes remain understudied using prospective
longitudinal designs [10]. The current study addresses this gap
by exploring longitudinal associations between HIV stigma,
Earnshaw VA et al. Journal of the International AIDS Society 2018, 21:e25198
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25198/full | https://doi.org/10.1002/jia2.25198
1
coping, ART initiation and HIV-1 RNA suppression among
PLWH in South Africa.
HIV stigma is conceptualized as a social process that exists
when labelling, stereotyping, separation and discrimination of
PLWH occur within a power structure [8]. This social process,
in turn, is experienced by individuals as a series of stigma
mechanisms [11]. Internalized stigma involves endorsing nega-
tive beliefs and feelings about PLWH and applying them to
the self [11]. Internalized stigma may be particularly high in
the first few weeks after HIV diagnosis and then decreases
over time [12]. HIV stigma mechanisms are associated with
lower likelihood of ART adherence [10,13], and internalized
HIV stigma appears to play a prominent role in treatment-
related behaviours. In a cross-sectional study of PLWH in the
United States, internalized stigma was associated with lower
likelihood of ART adherence after controlling for enacted and
anticipated stigma (i.e. past experiences of discrimination and
future expectations of discrimination) [14]. Other cross-sec-
tional studies in the United States and Canada have also
found associations between internalized stigma and lower like-
lihood of ART adherence [15,16] as well as ART initiation [17].
Although generally understudied in longitudinal studies, one
longitudinal study in the United States found no significant
prospective association between internalized stigma and ART
adherence one month later [18]. No known longitudinal stud-
ies have examined the prospective association between inter-
nalized stigma and ART initiation.
Internalized stigma may be associated with a lower likeli-
hood of ART initiation, in part, because it compromises adap-
tive coping. Coping is the process of managing demands
created by stressful events that are perceived as exceeding
one’s resources [19,20]. Receiving an HIV diagnosis and need-
ing to initiate ART may be experienced as stressful events
[21] that exceed one’s psychological, social and/or financial
resources [22]. Coping processes can be adaptive, helping
people to respond to stressors in positive or healthy ways
(e.g. approach or problem-focused coping), or maladaptive,
leading people to respond to stressors in negative or
unhealthy ways (e.g. avoidant coping) [20]. Internalized stigma
may lead to maladaptive coping in part because it undermines
hope and self-esteem [23]. Maladaptive coping, in turn, under-
mines engagement in health behaviours: Avoidant coping is
associated with lower medication adherence and higher HIV-1
RNA among PLWH [24].
We hypothesized that: (1) internalized stigma is associated
with lower likelihoods of ART initiation and HIV-1 RNA sup-
pression over the first nine months post-HIV diagnosis; and
(2) maladaptive coping mediates these associations.
2 | METHODS
2.1 | Context
The study took place between July 2014 and July 2015 in
Soweto and Gugulethu, which are urban, densely populated
townships in South Africa predominately inhabited by black
South Africans. National estimates indicate a high prevalence
of internalized stigma (43%) among PLWH in South Africa [9].
In resource-poor areas, internalized stigma may be particularly
salient due to a strong interplay between socio-economic
inequalities and stigma, with higher socio-economic status
associated with lower internalized stigma [25]. In an urban,
resource-poor area of Cape Town, 58% of patients referred
for HIV treatment by a mobile clinic reported feeling either
guilty of ashamed that they have HIV [26]. Individuals were
recruited from HIV testing centres for this study. At one site
in Soweto, the testing centre was part of a research unit.
Otherwise, testing centres were housed within community
health centres wherein they were integrated with other care
(e.g. primary care, HIV treatment).
2.2 | Participants
Individuals were tested for HIV and immediately given their
results. Those who tested positive had blood drawn for a CD4
count and were advised to return a week later for results.
Participants included 500 ART-eligible adults (18 years or
older) who were recruited as they received their CD4 count
results. ART eligibility was determined based on South African
guidelines (CD4+ ≤ 350 cells/mm3 before 1 January 2015
and CD4+ < 500 cells/mm3 after 1 January 2015). Children
and pregnant women were excluded from participating
because they qualified for intensive adherence support.
2.3 | Procedures
Trained multilingual interviewers, who were independent from
the clinical staff, delivered an in-person survey using Research
Electronic Data Capture (REDCap) [27]. Self-report data,
including internalized stigma and coping, were collected from
participants one week following their HIV diagnosis and three
months later. Medical data, including ART initiation and HIV-1
RNA, were extracted from the National Health Laboratory
Service (NHLS) database at six and nine months post-baseline
by a study team member. NHLS provides laboratory services
to all public-sector facilities in South Africa. Study procedures
received Institutional Review Board approval from Human
Subjects Committees at Partners Healthcare, the University of
Witwatersrand Ethics Committee, the Gauteng Department of
Health and the University of Cape Town Ethics Committee,
and all participants provided informed consent.
2.4 | Measures
Internalized HIV stigma was measured with the Internalized
AIDS-Related Stigma Scale [28]. Other experiences of stigma,
such as enacted and anticipated stigma, were not measured.
The Internalized AIDS-Related Stigma Scale asks participants
whether they “agree” (1) or “disagree” (0) with six statements.
Results of an exploratory factor analysis using the baseline
data suggested a two-factor solution accounting for 69.25% of
the variance in the scale. The first factor included four inter-
nalized stigma items capturing feelings of shame, worthless-
ness, guilt and dirty, and the second factor included two
disclosure concerns items. The disclosure items were there-
fore dropped from the scale. The remaining internalized
stigma subscale had adequate reliability (Cronbach’s
alpha = 0.81), and a mean composite score was created to
represent internalized stigma.
Maladaptive coping was measured with 12 items from the
Brief COPE measuring self-distraction, denial, substance use,
disengagement, venting and self-blame [29]. Items from the
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self-blame subscale regarding self-criticism and self-blame that
conceptually overlapped with internalized stigma were first
removed. An initial factor analysis suggested a three-factor
solution accounting for 62.34% of the variance in the scale;
however, it included one item that did not load well onto any
subscale (“I’ve been saying to myself ‘this isn’t real’”; factor
loadings < 0.40). After this item was deleted, an additional
factor analysis was conducted that suggested a two-factor
solution accounting for 54.50% of the variance in the scale.
One factor included six items related to avoidance, denial and
negative emotion release. This avoidance subscale had ade-
quate reliability (Cronbach’s alpha = 0.76). A mean composite
score was created to represent the construct.
Following previously validated procedures for imputing
dates of treatment initiation using NHLS data [30], ART initia-
tion by six months was determined based on a measure of
creatinine. Plasma RNA results were directly entered into
NHLS by clinical providers, and HIV-1 RNA suppression by
nine months was calculated (<50 copies/mL).
Participants reported their age, sex, ethnicity, relationship
status, education and employment at the baseline study inter-
view. They also reported their binge drinking (calculated from
number of drinks per day), recreational drug use and tobacco
use in the past 30 days.
2.5 | Analyses
First, descriptive analyses were conducted using SPSS [31] to
characterize the socio-demographic and other relevant charac-
teristics of the sample. Second, all correlations between inter-
nalized stigma at one week after HIV diagnosis, avoidant
coping at three months, ART initiation at six months and HIV-
1 RNA suppression at nine months were examined. Correla-
tions between socio-demographic characteristics and these
variables were also explored. Pearson’s correlations were used
for correlations between continuous variables, point-biserial
between continuous and dichotomous variables, and Spear-
man’s rho between dichotomous variables.
Third, two path analyses were conducted using Mplus ver-
sion 8 [32] to test for longitudinal mediation [33]. The first
model included ART initiation as the dependent variable, and
the second model included HIV-1 RNA suppression as the
dependent variable. Associations between internalized stigma
at one week post-diagnosis with avoidant coping at three
months post-diagnosis were modelled following recommenda-
tions for longitudinal analyses by controlling for avoidant cop-
ing at one week [34]. Associations between avoidant coping at
three months with ART initiation at six months post-diagnosis
and HIV-1 RNA suppression at nine months post-diagnosis
were also modelled. The effects of socio-demographic charac-
teristics and substance use that were correlated with the
mediator (avoidant coping) and/or outcomes (ART initiation
and HIV-1 RNA suppression) were controlled for on both the
mediator and outcomes, and models controlled for clustering
by study site via standard error adjustment using a sandwich
estimator. Socio-demographic characteristics and substance
use variables that were not statistically significant in the multi-
variate path analyses were trimmed from the final model [35].
Following recommendations for mediation testing with
dichotomous outcomes [36–38], counterfactually based indi-
rect effects for links between baseline internalized HIV stigma
and the distal outcomes ART initiation and HIV-1 RNA sup-
pression via the mediator of three-month avoidant coping
were estimated.
3 | RESULTS
Of the 500 participants enrolled in the study, 14 (2.8%) did
not respond to one of the substance use questions at baseline
and an additional 88 (18.5%) did not complete the three-
month survey. These 102 individuals with missing data were
excluded from the analyses, resulting in an analytic sample of
398 participants. Sample characteristics, including socio-demo-
graphic data, are displayed in Table 1 and reflected those of
patients at the data collection sites. Participants who did not
identify as Zulu or Xhosa identified as Sesotho (5.8%), Tsonga
(2.3%) or another ethnicity (e.g. Tswanga, Venda, N. Sotho).
Fewer participants who were single (17.6%; X2(1) = 5.69,
p = 0.02) or virally suppressed (14.7%; X2(1) = 7.24; p = 0.01)
were excluded from the analytic sample than those who were
included. Conversely, more engaged in recreational drug use
(18.6%; X2(1) = 36.23, p < 0.01).
As shown in Table 2, internalized stigma at one week after
HIV diagnosis was positively correlated with avoidant coping
at three months. Avoidant coping was negatively correlated
with ART initiation at six months and HIV-1 RNA suppression
at nine months.
The first model, predicting ART initiation at 6 months,
demonstrated good fit to the data (X2(7) = 8.14, p = 0.32;
RMSEA = 0.02 (90% CI = 0.00 to 0.07); comparative fit index
(CFI) = 0.92). As shown in Figure 1, internalized stigma at one
week was associated with avoidant coping at three months.
Table 1. Sample characteristics (n = 398)




Zulu ethnicity 17.6 (70)
Xhosa ethnicity 64.6 (257)
Single relationship status 70.6 (281)
High school education 26.1 (104)
Employed 43.5 (173)
Recreational drug use 2.8 (11)
Binge drinking 46.2 (184)
Tobacco use 24.4 (97)
Internalized stigma, 1 week 0.26 (0.34) 46.5 (185)
Avoidant coping
1 week 1.60 (0.68)
3 months 1.32 (0.55)
ART initiation, 6 months 57.3 (228)
HIV-1 RNA suppression, 9 months 27.6 (110)
Internalized stigma scores ranged 0 to 1 and coping scores ranged 1
to 4. The mean internalized stigma score and percentage of partici-
pants who agreed with at least one internalized stigma item are
reported.
ART, antiretroviral therapy.
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Avoidant coping at three months was associated with lower
likelihood of ART initiation at six months. Additionally, partici-
pants who were not Xhosa (B(SE) = 0.31(0.13), p = 0.01)
engaged in more avoidant coping. The remaining socio-demo-
graphic variables and substance use variables were not asso-
ciated with avoidant coping or ART initiation. A significant
counterfactually based indirect effect of internalized stigma on
ART initiation via avoidant coping was also observed (total
natural indirect effect: OR = 1.04, p = 0.04).
The second model, predicting HIV-1 RNA suppression at
9 months, also demonstrated good fit to the data (X2(7)
= 6.58, p = 0.47; RMSEA = 0.00 (90% CI = 0.00 to 0.06);
CFI = 1.00). As shown in Figure 2, internalized stigma at one
week was again associated with avoidant coping at three
months. Avoidant coping at three months was associated with
lower likelihood of HIV-1 RNA suppression at nine months.
Additionally, participants who were not Xhosa, engaged in
more avoidant coping (B(SE) = 0.34(0.13), p = 0.01). The
remaining socio-demographic variables and substance use
were not associated with avoidant coping or HIV-1 RNA sup-
pression in this model. A significant counterfactually based
indirect effect of internalized stigma on HIV-1 RNA suppres-
sion via avoidant coping was also observed (total natural indi-
rect effect: OR = 1.07, p < 0.01).
4 | DISCUSSION
Results of this longitudinal study of 398 South African PLWH
contribute to understanding of whether and how internalized
HIV stigma is associated with deleterious HIV treatment and
physical health outcomes. Previous cross-sectional work has
suggested that internalized HIV stigma is associated with a
lower likelihood of ART initiation [17]. The current study
extends this research by demonstrating that internalized
stigma measured one week after HIV diagnosis is prospec-
tively associated with both non-initiation of ART at six months
as well as unsuppressed HIV-1 RNA at nine months. The asso-
ciations between internalized stigma and these outcomes
were mediated, and results reflected inconsistent mediation
(i.e. the signs of the mediated effect were opposite of the
signs of the direct effects) [38]. In cases of inconsistent medi-
ation, the direct effect between an independent variable and
dependent variable is non-significant despite the existence of
a significant indirect effect between the variables [38]. In the
current study, the direct effects between internalized stigma
with ART initiation and HIV-1 RNA suppression were non-sig-
nificant despite the existence of significant indirect effects
between these variables. One previous longitudinal study did
not find a direct association between internalized stigma and









Avoidant coping, 3 months 0.23** 1
ART initiation, 6 months 0.03 0.10* 1
HIV-1 RNA suppression,
9 months
0.02 0.13** 0.53** 1
Age 0.05 0.01 0.08 0.04
Female 0.01 0.01 0.05 0.04
Zulu ethnicity 0.07 0.33** 0.11* 0.09
Xhosa ethnicity 0.22** 0.48** 0.14** 0.13*
Single relationship status 0.01 0.01 0.06 0.10
High school education 0.05 0.20** 0.04 0.05
Employed 0.01 0.06 0.01 0.01
Recreational drug use 0.11* 0.17** 0.04 0.04
Binge drinking 0.02 0.01 0.01 0.03
Tobacco use 0.06 0.05 0.04 0.01
**p < 0.01, *p < 0.05.
ART, antiretroviral therapy.
Figure 1. Longitudinal structural equation model of associations between internalized stigma, avoidant coping and antiretroviral therapy
initiation.
Values are unstandardized regression coefficients. Model controls for socio-demographics and substance use on avoidant coping at three months
and ART initiation at six months. **p < 0.01
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ART adherence [18]. This non-significant finding may have also
been due to inconsistent mediation (i.e. internalized stigma
may have been associated with ART adherence in this previ-
ous study via an untested mediator) or differences in the
dependent variables (i.e. internalized stigma may play different
roles in ART initiation vs. adherence).
Our results further suggest that maladaptive coping mediates
associations between internalized HIV stigma with ART initia-
tion and HIV-1 RNA suppression. Internalized HIV stigma may
lead PLWH to engage in efforts to avoid, deny and distract
themselves from stressors, which in turn reduces the likelihood
of ART initiation and HIV-1 RNA suppression. Previous cross-
sectional studies have identified depressive symptoms, loneli-
ness, low perceived social support, attachment-related anxiety
and HIV disclosure concerns as mediators of associations
between internalized HIV stigma and ART-related outcomes,
including initiation and adherence [15-17]. It is possible that the
process linking internalized HIV stigma with ART initiation and
HIV-1 RNA involves serial mediation of these psychosocial vari-
ables. For example, internalized HIV stigma may lead to greater
depressive symptoms, which in turn may lead to greater avoi-
dant coping, ART non-initiation and unsuppressed HIV-1 RNA.
The process linking internalized HIV stigma with ART non-initia-
tion and HIV-1 RNA non-suppression may also involve multiple
pathways. Future research exploring multiple psychosocial
mediators simultaneously can contribute to stronger under-
standing of the mechanisms linking internalized HIV stigma with
HIV treatment and health outcomes.
4.1 | Strengths, limitations and future directions
These results add to the literature on associations between
internalized HIV stigma with treatment and physical health
outcomes. Much of the previous research examining these
associations has been cross-sectional [14,15,17], limiting possi-
bilities for forming firm conclusions regarding prospective
associations between variables. The current study answers a
call for longitudinal research testing prospective associations
between stigma and ART outcomes, and for identifying media-
tors of these associations [10]. Results of this longitudinal
study suggest that internalized HIV stigma one week after
HIV diagnosis is associated with avoidant coping at three
months, controlling for avoidant coping one week after HIV
diagnosis. Moreover, results suggest that internalized stigma
one week after HIV diagnosis is associated with lower likeli-
hoods of ART initiation at six months and HIV-1 RNA sup-
pression at nine months. Direct effects between internalized
stigma with ART initiation and HIV-1 RNA suppression were
not statistically significant, but indirect effects reflecting incon-
sistent mediation were observed. Future researchers examin-
ing associations between internalized stigma with similar
outcomes should note that indirect effects may exist between
these variables even if direct effects are not statistically signif-
icant, and therefore, it may be important to explore mediators
to fully understand these associations.
The current study focused on the role of internalized HIV
stigma in treatment and physical health outcomes. Other stud-
ies have focused on other HIV stigma mechanisms, including
enacted and/or anticipated stigma [13,39]. Future research
that includes multiple HIV stigma mechanisms can contribute
to our understanding of which stigma mechanisms are the
most robust predictors of HIV treatment and health out-
comes. Additionally, participants may experience stigma associ-
ated with other socially devalued characteristics (e.g. race,
gender). Future longitudinal research should examine the
extent to which and mechanisms whereby these other forms
of stigma are associated with HIV treatment and physical
health outcomes. Future research may also include measures
of resilience resources, such as adaptive coping strategies and
social support, to provide insight into who is resilient to the
deleterious effects of HIV stigma.
ART initiation by six months after HIV diagnosis was
abstracted from South Africa’s NHLS. Participants may have
initiated ART before six months. Prior research focused on
associations between ART initiation and subsequent changes in
internalized HIV stigma [40] suggest that ART initiation may
lead to decreases in internalized HIV stigma. Future studies
incorporating more precise data on when ART is initiated can
continue to clarify temporal associations between stigma, cop-
ing and ART initiation. Future work should measure ART
adherence in addition to ART initiation and HIV-1 RNA to fur-
ther elucidate associations between internalized stigma, coping
and these outcomes. Participants who provided incomplete
data were excluded from the analyses. Fewer single and virally
suppressed participants provided incomplete data than those
who were included in the analyses, and more engaged in recre-
ational drug use. Future research is needed to examine the
extent to which findings generalize to participants who were
underrepresented in the current analysis. Finally, it is impor-
tant to study these associations within South Africa given find-
ings suggesting that over 40% of the 7.2 million PLWH living
in South Africa have internalized some degree of stigma, 39%
are not currently receiving ART and 53% have unsuppressed
HIV-1 RNA [6,9]. Yet, future research is needed to determine
whether these findings generalize to other sociocultural con-
texts.
Figure 2. Longitudinal structural equation model of associations between internalized stigma, avoidant coping and HIV-1 RNA suppression.
Values are unstandardized regression coefficients. Model controls for socio-demographics and substance use on avoidant coping at three months
and HIV-1 RNA suppression and nine months. **p < 0.01




Greater understanding of the role of internalized stigma in
HIV treatment and physical health outcomes, including the
mechanisms linking stigma with these outcomes, can inform
intervention efforts to promote the wellbeing of PLWH. The
current study suggests that it may be important to address
internalized HIV stigma and maladaptive coping among individ-
ual PLWH to promote ART initiation and HIV-1 RNA suppres-
sion. There is some evidence to suggest that livelihood
interventions that enhance economic empowerment may
reduce internalized HIV stigma, possibly by weakening sym-
bolic associations between HIV and economic incapacity, ill-
ness and death [41,42]. Interventions that focus on other
forms of empowerment, such as pride, may further reduce
internalized stigma [43]. It may also be possible to teach or
strengthen adaptive coping strategies (e.g. support seeking)
and decrease use of maladaptive coping strategies (e.g. avoid-
ance and denial). Interventions involving coping effectiveness
training and teaching cognitive behavioural stress management
techniques have led to improved psychosocial outcomes,
including reduced stress, among PLWH [20,44]. It may be par-
ticularly important to assess and address internalized stigma
and coping strategies soon after HIV diagnosis to facilitate
timely initiation of ART. Ultimately, it is important to eliminate
HIV stigma so that no individual person diagnosed with HIV is
at risk of internalizing HIV stigma and experiencing the nega-
tive downstream effects of internalized HIV stigma on dimin-
ished coping, ART non-initiation and unsuppressed HIV-1
RNA. Researchers, clinicians and policymakers should continue
to develop and evaluate strategies to address HIV stigma and
promote the wellbeing of PLWH in South Africa and globally.
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